Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe PreeclampsiaStatus: open
17-019 - A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia
Treatment for Preeclampsia
This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
SponsorsThis trial is sponsored by Velo Bio, LLC.
Interested in Clinical Trial?
Providers Associated With This Trial
- Bassam H. Rimawi, M.D.Maternal-Fetal PhysicianAssistant Professor of Obstetrics and Gynecology